Werewolf Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Werewolf Therapeutics Stock-Based Compensation Growth & History (HOWL)
Werewolf Therapeutics's stock-based compensation was $6.2M for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.2M | −$2.6M | −29.24% |
| 2024 | 2024-12-31 | $8.8M | $818,000 | +10.21% |
| 2023 | 2023-12-31 | $8.0M | $608,000 | +8.22% |
| 2022 | 2022-12-31 | $7.4M | $3.3M | +80.71% |
| 2021 | 2021-12-31 | $4.1M | $3.5M | +547.94% |
| 2020 | 2020-12-31 | $632,000 | — | — |
Werewolf Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $419,000 | −$1.4M | −76.63% |
| Q1 2026 | 2026-03-31 | $929,000 | −$1.1M | −53.69% |
| Q4 2025 | 2025-12-31 | $1.2M | −$695,000 | −36.43% |
| Q3 2025 | 2025-09-30 | $1.2M | −$778,000 | −38.69% |
| Q2 2025 | 2025-06-30 | $1.8M | −$809,000 | −31.09% |
| Q1 2025 | 2025-03-31 | $2.0M | −$299,000 | −12.97% |
| Q4 2024 | 2024-12-31 | $1.9M | $35,000 | +1.87% |
| Q3 2024 | 2024-09-30 | $2.0M | −$86,000 | −4.10% |
| Q2 2024 | 2024-06-30 | $2.6M | $672,000 | +34.82% |
| Q1 2024 | 2024-03-31 | $2.3M | $197,000 | +9.35% |
| Q4 2023 | 2023-12-31 | $1.9M | −$69,000 | −3.55% |
| Q3 2023 | 2023-09-30 | $2.1M | $161,000 | +8.32% |
| Q2 2023 | 2023-06-30 | $1.9M | $153,000 | +8.61% |
| Q1 2023 | 2023-03-31 | $2.1M | $363,000 | +20.80% |
| Q4 2022 | 2022-12-31 | $1.9M | $646,000 | +49.85% |
| Q3 2022 | 2022-09-30 | $1.9M | $457,000 | +30.90% |
| Q2 2022 | 2022-06-30 | $1.8M | $996,000 | +127.53% |
| Q1 2022 | 2022-03-31 | $1.7M | $1.2M | +223.75% |
| Q4 2021 | 2021-12-31 | $1.3M | $1.1M | +486.43% |
| Q3 2021 | 2021-09-30 | $1.5M | $1.3M | +1012.03% |
| Q2 2021 | 2021-06-30 | $781,000 | $560,000 | +253.39% |
| Q1 2021 | 2021-03-31 | $539,000 | $482,000 | +845.61% |
| Q4 2020 | 2020-12-31 | $221,000 | — | — |
| Q3 2020 | 2020-09-30 | $133,000 | — | — |
| Q2 2020 | 2020-06-30 | $221,000 | — | — |
| Q1 2020 | 2020-03-31 | $57,000 | — | — |
Werewolf Therapeutics stock-based compensation trends
Over the last five fiscal years, Werewolf Therapeutics's stock-based compensation increased from $632,000 to $6.2M, a change of $5.6M. The latest reported quarter, Q2 2026, shows $419,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗